We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States.
- Authors
Liu, Maobai; Han, Sijie; Zheng, Bin; Cai, Hongfu; Yang, Jing; Zhuang, Qian; Li, Na
- Abstract
Background: Pembrolizumab, a programmed cell death-1 (PD-1) inhibitor, has recently gained prominence as a second-line treatment for recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC). This study compares the acceptance and different influencing factors of pembrolizumab in the treatment of R/M HNSCC in developed (i.e., the United States) and developing (i.e., China) countries through cost-effectiveness analysis and provides valuable suggestions for clinical decision making. Methods: A Markov model was constructed using TreeAge Pro 2015 software to evaluate the economic value of four treatment strategies. Quality-adjusted life years (QALY) and incremental cost-effectiveness ratio (ICER) were used as economic indicators for incremental cost-effectiveness analysis. The stability of the model was evaluated by one-way sensitivity and probability sensitivity analyses. Results: The ICERs for the pembrolizumab group versus PD-L1 CPS treatment in China and the US were $7892/QALY and $11,900/QALY, respectively. All ICERs were less than the threshold of $29,306 in China and $50,000 in the US; thus, pembrolizumab is cost effective. Sensitivity analysis confirmed a stable economic advantage in the single-drug regimen of pembrolizumab in China and the US. Conclusion: Pembrolizumab monotherapy as a second-line treatment for R/M HNSCC presents more health benefits in comparison with the standard, PD-L1 TPS and PD-L1 CPS groups in China and the US.
- Subjects
CHINA; SQUAMOUS cell carcinoma; PEMBROLIZUMAB; QUALITY-adjusted life years; COST effectiveness; ECONOMIC indicators
- Publication
Cancer Management & Research, 2019, Vol 11, p9483
- ISSN
1179-1322
- Publication type
Article
- DOI
10.2147/CMAR.S226243